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43eta-blockers in combination with quinidine were given to 233 In connexion with the duration of atrial fibrillation, the conversion to sinus rhythm was oblained in 76 4 per cent of the cases with a fibrillation of less than 6 months' duration and in 35 9 per cent with more than 6 months. Toxic effects and intolerance to treatment are clearly less than with quinidine alone, which is probably due to a synergism between the two drugs, and as a consequence of the beta-blocker ,depressant effects on ventricular excitability which avoids the onset of severe arrhythmias. e1he treatment of chronic atrial fibrillation with DC shock which initially met with great enthusiasm, is now becoming less popular as a consequence of the complications (Resnekov, I970) and fatalities (2%, according to recent data: Resnekov, 1970) , connected with DC conversion and the demonstration that most subjects (72%, according to Szekely, Sideris, and Batson, 1970) Subsequently we have treated groups of patients with an association of quinidine and more recently beta-blockers, such as alprenolol, LB 46, and practolol (Levi and Proto, 1970a, I972) .
The chemical structure of these latest betablockers differs from propranolol particularly in the replacement of the naphtalenic nucleus with the indolic one for LB 46 (Lubawski and Wale, I969) and a benzenic one for alprenolol and practolol (Brandstrom et al., I966; Dollery, Paterson, and Conolly, I969) .
Pharmacologically, practolol differs from propranolol by the absence of a membrane activity or quinidine-like effect and by the presence of obvious cardioselectivity (Dunlop and Shanks, I968) and, like alprenolol and LB 46, by an intrinsic sympathicomimetic effect, lacking in propranolol (Hill and Turner,   I969 ; Ablad, Brogard, and Ek, I967) (Table   I ). Subjects with bronchial asthma and obstructive bronchopathies without respiratory insufficiency were treated with quinidine combined with alprenolol, LB 46, or practolol, which, unlike propranolol, and because of their intrinsic betastimulating effect, have poor activity on bronchial smooth muscle.
We followed Stem's therapeutic schedule (Stem, I966) by administering a dose of betablocker every 6 hours for two to four days to reach an average ventricular rate of 6o to 8o beats/min. At this time quinidine was added (hydroquinidine IS centigrammes with any single dose of betablocker). The combined treatment was carried on for another four to five days until atrial fibrillation was converted to sinus rhythm. To maintain sinus rhythm, treatment was continued indefinitely at slightly reduced doses.
The combined treatment was withdrawn after five to seven days when sinus rhythm failed to be achieved, or earlier in some rare cases of pharmacological intolerance. Alprenolol, LB 46, and practolol were administered at a pharmacologically determined dosage, corresponding to the beta-blocking effect obtained with propranolol, 20 mg. The doses were propranolol 20 mg; alprenolol 50 mg; practolol ioo mg; LB 46 5 mg; 4 times a day.
The results of the trial confirmed that the therapeutic effects of these doses were the same. In fact we were able to show the similar effect of the 4 drugs by calculating the average reduction of heart rate in patients with re-established sinus rhythm (Table 2) .
Results
A combination of quinidine and beta-blockers (Table 3) was administered to 233 patients with chronic atrial fibrillation. Of I22 patients treated with propranolol and quinidine, of whom 59 had coronary artery disease, 48 valvular heart disease, 8 idiopathic atrial fibrillation, 6 thyrotoxic heart, and 2 congenital heart disease, sinus rhythm was re-established in 79 patients (64-8%).
In 32 patients we tried to restore sinus rhythm with the association of alprenololquinidine, with a favourable result in 56 2 per cent of the cases (i8 subjects). Of the 32 patients with chronic atrial fibrillation, IS had coronary artery disease, I3 valvular heart disease, and 4 thyrotoxic hearts.
Of 44 patients treated with LB 46 -quinidine combination, 20 had sclerotic heart disease, 17 valvular heart disease, 4 idiopathic atrial fibrillation, 2 thyrotoxic hearts, and i luetic heart disease. Conversion to sinus rhythm was obtained (65'9%) in 29 subjects.
The combination ofpractolol-quinidine was given to 35 patients, i8 of whom had sclerotic heart disease and I7 valvular heart disease; i6 responded (4517%).
To provide evidence that the duration of atrial fibrillation is a key factor to the success of the therapy, we divided the patients into 2 groups according to the duration of arrhythmias (less or more than 6 months) (Table 4) .
In the first group we obtained conversion to sinus rhythm in 84-4 per cent of cases with Of 79 patients treated with the propranololquinidine combination with conversion to sinus rhythm, 56 were controlled after 6 months. 73-2 per cent maintained the sinus rhythm even when the combined treatment X was not followed constantly; this result is clearly better than those already reported for treatment with quinidine alone. With the exception of sporadic ventricular extrasystoles, no electrocardiographic abnormality due to the drugs was observed during the trial either before or after conversion (Proto et al., I969, I97I) . No sudden death due to cardiac arrest or ventricular fibrillation occurred in any of our subjects. We recorded quinidine-induced toxic signs in 4-8 per cent (9 cases) but never of a severe type (5 cases in the group treated with propranolol, 2 cases in the LB 46 group, i in the group treated with alprenolol, and i with practolol). Cerebral embolism occurred in 2 patients treated with quinidine and practolol on the second and the fifth day after conversion to sinus rhythm. The treatment was continued with quinidine alone 400 mg/day intramuscularly. The beta-blocker withdrawal caused serious electrocardiographic abnormalities, particularly with reference to QT and the morphology of the T wave (Fig.) , confirming that the beta-blockers probably provide a safeguard against some quinidine-induced electrocardiographic abnormalities.
For these reasons we think that treatment with quinidine-beta-blockers is a useful combination for chronic atrial fibrillation, because of the rapidity of response and its ability to maintain sinus rhythm; in particular, these 2) The depressant effect of beta-blockers on ventricular excitability prevents the onset of severe arrhythmias.
3) The percentage of subjects who remain in sinus rhythm after 6 months is clearly higher than after electrical conversion.
